CD8A and AIDS: The CD4/CD8 in controls [0.70 (IQR 0.48–0.94)] was significantly higher compared to the ratio in subjects who developed non-AIDS events [0.46 (IQR 0.31–0.68), P<0.0001], including non-AIDS defining malignancies (N = 35) [0.44 (IQR 0.25–0.71), P = 0.0001], Hodgkin lymphoma (N = 10) [0.41 (IQR 0.33–0.57), P = 0.0039], ischemic heart disease (N = 38) [0.47 (IQR 0.32–0.63), P = 0.0001], stroke (N = 15) (0.46 [IQR 0.28–0.83), P = 0.013), and end-stage kidney disease (N = 9) [0.33 (0.32–0.53), P = 0.028].